NASDAQ:CLSN
Delisted
Celsion Corporation Stock News
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020
12:30pm, Friday, 07'th Aug 2020
LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarte
Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
12:30pm, Tuesday, 04'th Aug 2020
Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the Trial
Celsion Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
03:53pm, Tuesday, 28'th Jul 2020
Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
12:30pm, Monday, 27'th Jul 2020
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for Long-Ter
Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?
12:56pm, Tuesday, 21'st Jul 2020
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Celsion (CLSN) Stock Loses a Wall Street Supporter
02:26am, Saturday, 18'th Jul 2020
Stocks go up, stocks go down, you can't explain that...Or maybe you can, if the stock happen to be a biotech that just flunked a clinical trial. Which leads us nicely to Celsion Corporation (CLSN).
Celsion Down on DMC Recommendation to Stop Liver Cancer Study
02:49pm, Tuesday, 14'th Jul 2020
Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
12:30pm, Tuesday, 14'th Jul 2020
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its curren
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall.
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
12:00am, Monday, 13'th Jul 2020
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
Edited Transcript of CLSN earnings conference call or presentation 15-May-20 3:00pm GMT
12:18am, Sunday, 28'th Jun 2020
Q1 2020 Celsion Corp Earnings Call
Celsion (NASDAQ:CLSN) Rating Reiterated by Dawson James
05:56am, Friday, 26'th Jun 2020
Celsion (NASDAQ:CLSN)‘s stock had its “buy” rating restated by equities research analysts at Dawson James in a report issued on Wednesday, AnalystRatings.com reports. They presently have a $4.00
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
12:00pm, Thursday, 25'th Jun 2020
Celsion Corporation (CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the
Celsion Corporation Announces Closing of Public Offering of Common Stock
08:15pm, Wednesday, 24'th Jun 2020
Celsion Corporation (CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds
3 "Strong Buy" Penny Stocks With Triple-Digit Upside Potential
02:43pm, Wednesday, 24'th Jun 2020
COVID-19 and the ensuing economic shutdowns have changed the rules of the investing game. Amid this unprecendented market shakeup, investors must navigate
